To confirm the robustness of the observed phenotype SOD1 knockdown was performed in primary glioma cells NCH 690 and a SOD1 CRISPR/Cas9 knockout was performed in LN-229 cells. This evidence concerns the gene SOD1 and central nervous system cancer.